S
Shanghai Kangkang Biotechnology
Prodrugs of immune-stimulating agents and multi-specific biologics
About Shanghai Kangkang Biotechnology
Shanghai Kangkang Biotechnology (KangaBio) is a clinical-stage biotechnology firm established in 2021 by Dr. Weidong Jiang and headquartered in Shanghai's Zhangjiang Biomedicine Valley. The company focuses on developing immunotherapeutics for cancer treatment, specifically prodrugs of immune-stimulating agents and multi-specific biologics designed to reduce toxicity and enhance efficacy.
The founder and CEO, Dr. Weidong Jiang, has an extensive background in the biotechnology industry. He earned his Ph.D. from Giessen University in Germany and completed post-doctoral work at the University of California. His career includes senior scientific and directorial roles at companies like Millennium/Takeda, Eli Lilly, and Catalyst Biosciences. Dr. Jiang previously co-founded Shanghai Henlius Biotech in 2009, which became a publicly listed company on the Hong Kong stock exchange and successfully launched multiple biologics in Chinese and European markets. The CMC (Chemistry, Manufacturing, and Controls) Vice President is Dr. Haixiang Wu, who has nearly two decades of experience in new drug R&D, with a focus on recombinant protein and antibody drugs.
KangaBio's business model centers on the research, development, and commercialization of its proprietary and licensed drug candidates. The company's pipeline includes KGX101, an engineered interleukin-12 (IL-12) prodrug that has completed its first patient dosing in China and has received IND approval in the United States. Other pipeline products include KGX103, a procytokine with antitumor functions, and KGX105, a T-cell engager for solid and advanced tumors. KangaBio has engaged in strategic collaborations, including a licensing agreement with Sanyou Biopharmaceuticals for a monoclonal antibody drug. In June 2023, the company secured approximately CNY 200 million in a Seed funding round from investors including TEDA Venture Capital, Tigeryeah Capital, Tao Capital, and Ding Fu Investment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 15.7/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2023 | $28M | $110M | Tao Capital · Ding Fu Investment · TEDA Venture Capital · Tigeryeah Capital | ↗ |
Growth signals
Latest recorded traffic for Shanghai Kangkang Biotechnology is 1.1K monthly website visits, up 254.8% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Kangkang Biotechnology in its local ecosystem
The Shanghai Kangkang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Tao Capital- DIDing Fu Investment
- TCTEDA Venture Capital
- TCTigeryeah Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Kangkang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Kangkang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.